Quamatel 40mg 14 tablets — Made in Hungary — Free Delivery

Pharmacological properties

Famotidine is an effective competitive blocker of n2-histamine receptors in the stomach wall, and therefore reduces the secretion of gastric juice. under the action of the preparation, both the concentration and the amount of gastric juice decrease, and the secretion of pepsin corresponds to the released amount of gastric juice.

Both in healthy volunteers and in patients with increased secretion, famotidine equally reduces gastric secretion, both basal nocturnal and stimulated by pentagastrin, betazol, caffeine, insulin or vagus nerve stimulation. The action of 20 and 40 mg of famotidine lasts 10-12 hours. A single evening dose (20-40 mg) reduces the basal and nocturnal secretion of gastric juice. The blockage of gastric acid secretion at night is 86–94% and lasts at least 10 hours.

When using the same dose in the morning, the degree of blocking of gastric acid secretion by food stimulated within 3-5 hours is 76-84%, and after 8-10 hours - 25-30%.

The preparation practically does not affect either the "hungry" level of gastrin, or its level after a meal.

Famotidine has no effect on gastric emptying, pancreatic secretory function, hepatic circulation and portal blood flow.

Famotidine does not affect the enzyme system of the liver cytochrome P450, the level of hormones in the blood plasma, does not have an antiandrogenic effect.

Pharmacokinetics. The pharmacokinetic profile of famotidine is linear.

Absorption: Famotidine is absorbed quickly and completely. Bioavailability - 40–45%, regardless of the contents of the stomach, does not change with age. The bioavailability of famotidine is slightly affected by primary metabolism.

Distribution in the body: after oral administration of Cmax of famotidine in the blood plasma is noted after 1-3 hours. Repeated doses do not lead to cumulation of the preparation. The connection with blood plasma proteins is insignificant - 15–20%. T1 / 2 from blood plasma is 2.3-3.5 hours. In the presence of severe renal failure, T1 / 2 may increase by 20 hours.

Metabolism: metabolized in the liver, the only known metabolite is sulfoxide.

Excretion: renal clearance is 250–450 ml / min, which indicates tubular excretion. 25-30% of the dose taken orally is excreted in the urine unchanged, only a small amount of famotidine is excreted in the form of sulfoxide.

Indications

Stomach and duodenal ulcers, gastroesophageal reflux disease and other diseases accompanied by hypersecretion of gastric juice (for example, Zollinger-Ellison syndrome); prevention of recurrence of gastric and duodenal ulcers, prevention of aspiration of gastric contents during general anesthesia (Mendelssohn's syndrome).

Application

Duodenal ulcer: 40 mg once at bedtime or 20 mg 2 times a day (morning and evening). the duration of the course of treatment is usually 4–8 weeks. as monotherapy in the absence of n. pylori or as part of a combination therapy.

Stomach ulcer: 40 mg once a day for 4-8 weeks. As monotherapy in the absence of H. pylori or as part of combination therapy.

Gastroesophageal reflux disease: 20 mg 2 times a day in the morning and evening for 6 weeks, in the presence of esophagitis - 20-40 mg for 12 weeks.

Zollinger-Ellison syndrome: in patients who have not previously received therapy, the usual initial dose is 20 mg of the preparation every 6 hours. In the future, the dose is set individually, depending on the patient's condition. In patients who have previously received another preparation of the H2-blocker group, the initial dose of famotidine may be higher than 20 mg every 6 hours. The duration of the preparation should be clinically justified.

For the prevention of recurrence of gastric and duodenal ulcers: 20 mg once at bedtime.

Before general anesthesia in order to prevent aspiration of gastric contents: appoint 40 mg the night before and / or in the morning on the day of surgery.

Application in certain groups of patients

Renal failure Due to the fact that Kvamatel is excreted mainly by the kidneys, in the presence of severe kidney disease, the preparation is recommended to be used with caution.

With a creatinine clearance of 30 ml / min or a plasma creatinine level of 3 mg / 100 ml, the daily dose of the preparation should be reduced by 20 mg or the interval between doses should be increased (36–48 hours).

Childhood use. There is insufficient data on the safety and efficacy of Kvamatel in children.

Elderly patients. There is no need to adjust the dose of Kvamatel depending on the patient's age.

Contraindications

Hypersensitivity to the active substance or any components that make up the preparation; the period of pregnancy and lactation, children under 12 years of age (due to the lack of sufficient experience in using the preparation).

Side effects

Rarely, headache, dizziness, diarrhea, or constipation.

Rarely

General symptoms: fever, loss of appetite, fatigue.

On the part of the cardiovascular system: arrhythmias, AV block.

From the digestive system: cholestatic jaundice, increased activity of liver enzymes, nausea, vomiting, bloating, a feeling of dry mouth.

From the hematopoietic system: agranulocytosis, pancytopenia, leukopenia, thrombocytopenia.

Allergic reactions: anaphylaxis, angioedema, urticaria.

From the musculoskeletal system: muscle spasms, arthralgia.

From the side of the central nervous system: transient mental disorders (for example, hallucinations, confusion, anxiety, depression, fear).

From the respiratory system: bronchospasm.

On the part of the skin: toxic epidermal necrolysis, alopecia, acne, pruritus, dry skin.

Others: gynecomastia, which disappears on its own after the end of treatment.

Often there is no reliable connection between the appearance of these signs and the use of famotidine.

Special instructions

Before starting therapy, it is necessary to exclude ulcer malignancy by morphological examination of a biopsy sample from the ulcer area.

In severe liver diseases, the preparation is used with extreme caution in reduced doses.

Due to the fact that a cross-allergic reaction has been described between various preparations of the H2-blocker group, in the presence of hypersensitivity to another preparation in this group, Kvamatel should be used with caution.

In case of lactose intolerance, it should be borne in mind that each 20 mg famotidine tablet contains 105 mg of lactose, and each 40 mg tablet contains 90 mg of lactose.

Famotidine passes into breast milk, therefore, if it is necessary to use it during breastfeeding, breastfeeding should be discontinued.

There is no data on the effect of the preparation on the ability to drive vehicles or perform work requiring concentration and increased attention.

Interactions

Famotidine does not affect the enzyme system of cytochrome p450 of the liver and therefore does not change the metabolism of simultaneously used preparations, the biotransformation of which is carried out using this enzyme system. when combined with ketoconazole, due to an increase in the pH of the gastric juice, the absorption of ketoconazole may decrease, since it depends on the acidity of the gastric juice.

Antacids slightly reduce the absorption of famotidine, which has no clinical significance.

Overdose

Famotidine, administered at a dose of 800 mg / day for 1 year to patients with abnormal secretion of gastric juice, did not cause severe side effects. treatment: gastric lavage, symptomatic or supportive therapy, patient observation.

Storage conditions

In the dark place at a temperature of 15-30 ° C.